Skip to content

Sharing successes, challenges and daily happenings in the Department of Medicine

Rheumatology

Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis

ARTICLE: Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis AUTHORS: Iago Pinal-Fernandez, Angela Quintana, Jose Cesar Milisenda, Maria Casal-Dominguez, Sandra Muñoz-Braceras, Assia Derfoul, Jiram Torres-Ruiz, Katherine Pak, Stefania Dell'Orso, Faiza Naz, Gustavo… Read More »Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis

Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

ARTICLE: Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis AUTHORS: Anne R Bass, Noha Abdel-Wahab, Pankti… Read More »Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

ARTICLE: Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) AUTHORS: Michelle Petri, Ian N Bruce, Thomas Dörner, Yoshiya Tanaka, Eric… Read More »Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)